Brookfield Corporation reported record growth in fee-bearing capital and assets under management in Q2, driving a 15% year-over-year rise in distributable earnings per share. The company plans to enhance share accessibility and liquidity through corporate simplification by 2026. Despite a modest dividend yield of 0.67%, Brookfield supports $580 million in share buybacks and raised a record $77 billion in Q2, with new fee revenue expected from the Just Group mandate. This strong operational performance suggests potential for further stock gains.
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with advanced primary cutaneous melanoma resistant to anti-PD-1 therapy. The treatment showed a 41.7% overall response...
NEAR Protocol announced a Q3 Backers Summit scheduled for October 28. The event will focus on discussions about its House of Stake issuance proposal, updates on NEAR AI, and integration plans. Tokenomics and AI are key topics, with special guests exp...
